Edgewise Therapeutics (EWTX) Capital Expenditures (2020 - 2026)
Edgewise Therapeutics (EWTX) posted Capital Expenditures of $41000.0 for Q1 2026, down 73.03% sequentially from $152000.0 in Q4 2025, and down 6.82% YoY from $44000.0 in Q1 2025.
Edgewise Therapeutics (EWTX) Capital Expenditures (2020 - 2026) Analysis & Trends
Edgewise Therapeutics has reported Capital Expenditures for 7 years, with the latest figure at $41000.0 in Q1 2026.
- Quarterly Capital Expenditures fell 6.82% year-over-year to $41000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $196000.0 (up 450.0% YoY) and the FY2025 annual result came in at $199000.0, up 352.27% from the prior year.
- Capital Expenditures fell to $41000.0 in Q1 2026 per EWTX's latest filing, from $152000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $4.4 million in Q1 2023 and troughed at -$994000.0 in Q4 2024.
- A 5-year average of $502294.1 and a median of $161000.0 in 2023 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2023 and 2024: Capital Expenditures surged 1313.59% in 2023, then tumbled 717.39% in 2024.
- Over 5 years, Capital Expenditures stood at $257000.0 in 2022, then slumped by 37.35% to $161000.0 in 2023, then sank by 717.39% to -$994000.0 in 2024, then jumped by 115.29% to $152000.0 in 2025, then plunged by 73.03% to $41000.0 in 2026.
- According to Business Quant data, Capital Expenditures over the past three periods registered $41000.0, $152000.0, and -$31000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Edgewise Therapeutics | 4.76 Bn | 4.76 Bn | - | 32,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 32,000.00 |
| Jun 30, 2026 | 32,000.00 |
| Mar 31, 2026 | 41,000.00 |
| Mar 31, 2026 | 41,000.00 |
| Dec 31, 2025 | 152,000.00 |
| Dec 31, 2025 | 152,000.00 |
| Sep 30, 2025 | -31,000.00 |
| Sep 30, 2025 | -31,000.00 |
| Jun 30, 2025 | 34,000.00 |
| Jun 30, 2025 | 34,000.00 |
| Mar 31, 2025 | 44,000.00 |
| Mar 31, 2025 | 44,000.00 |
| Dec 31, 2024 | -994,000.00 |
| Dec 31, 2024 | -994,000.00 |
| Sep 30, 2024 | 922,000.00 |
| Sep 30, 2024 | 922,000.00 |
| Jun 30, 2024 | -28,000.00 |
| Jun 30, 2024 | -28,000.00 |
| Mar 31, 2024 | 144,000.00 |
| Mar 31, 2024 | 144,000.00 |